Metavia INC. (MTVA) — 10-Q Filings

10-Q Filings (6)

• MetaVia Narrows Losses Amid R&D Cuts, Cash Declines — Nov 6, 2025 Risk: high
  MetaVia Inc. (MTVA) reported a net loss of $3.377 million for the three months ended September 30, 2025, a significant improvement from the $5.652 million net l
• MetaVia Navigates Q2 with No Revenue, Relies on Private Placement — Aug 7, 2025 Risk: high
  MetaVia Inc. (MTVA) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue pharmaceutical development stage. The
• MetaVia Inc. Q1 2025 10-Q Filed — May 14, 2025 Risk: low
  MetaVia Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., i
• NeuroBo Pharma Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Gemphire Therapeutics Inc., reported financial resu
• NeuroBo Pharma Q2 2024: Assets $8.2M, Liabilities $4.9M — Aug 14, 2024 Risk: medium
  NeuroBo Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $8.221 million and total liabilities of $
• NeuroBo Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  NeuroBo Pharmaceuticals, Inc. (MTVA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. NeuroBo Pharmaceuticals, Inc. filed a 10-Q report for the peri

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX